Saturday, October 18, 2025 3:41:59 PM
Jesster, the last prediction I can remember from the company came at the Annual Meeting the end of June last year. As I remember it, the CEO indicated that by the end of 2025 we'd be a very different company. It hasn't happened yet, but she still has roughly 2-1/2 months to make it happen, I still believe she could.
Of course, I'd agree that she expected to get more done by now, but if we gain approval in the UK, I think she'll have met her minimum, if the EDEN's approve, better. Finally if we have an Annual Meeting, gain insight on many issues, like regulatory submissions to other regulators and plans for production capability, I believe she'll have essentially achieved what she was hoping to do at that Annual Meeting.
I do hope that she'll get that Annual Meeting in this year, frankly there was at least one year where there was no meeting. I believe that UK approval is the least she wants to achieve before the meeting, without it, if she has a meeting she knows it will be rather hostile, I can't blame her for not wanting that. By the same token, she needs more shares to be authorized and I don't think investors would turn it down as essentially, you're shooting yourself in the foot, or worse, if you do.
Gary
Of course, I'd agree that she expected to get more done by now, but if we gain approval in the UK, I think she'll have met her minimum, if the EDEN's approve, better. Finally if we have an Annual Meeting, gain insight on many issues, like regulatory submissions to other regulators and plans for production capability, I believe she'll have essentially achieved what she was hoping to do at that Annual Meeting.
I do hope that she'll get that Annual Meeting in this year, frankly there was at least one year where there was no meeting. I believe that UK approval is the least she wants to achieve before the meeting, without it, if she has a meeting she knows it will be rather hostile, I can't blame her for not wanting that. By the same token, she needs more shares to be authorized and I don't think investors would turn it down as essentially, you're shooting yourself in the foot, or worse, if you do.
Gary
Bullish
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
